296 related articles for article (PubMed ID: 12431818)
1. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
van Moorselaar RJ; Voest EE
Mol Cell Endocrinol; 2002 Nov; 197(1-2):239-50. PubMed ID: 12431818
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis and anti-angiogenic therapy in prostate cancer.
Mukherji D; Temraz S; Wehbe D; Shamseddine A
Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenesis: a possible treatment option for prostate cancer?
Longoria RL; Cox MC; Figg WD
Clin Genitourin Cancer; 2005 Dec; 4(3):197-202. PubMed ID: 16425989
[TBL] [Abstract][Full Text] [Related]
4. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Montico F; Kido LA; Hetzl AC; Cagnon VH
Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitors in the treatment of prostate cancer.
Adesunloye BA; Karzai FH; Dahut WL
Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic activity of prostate-specific antigen.
Fortier AH; Nelson BJ; Grella DK; Holaday JW
J Natl Cancer Inst; 1999 Oct; 91(19):1635-40. PubMed ID: 10511590
[TBL] [Abstract][Full Text] [Related]
7. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
Benelli R; Monteghirfo S; Balbi C; Barboro P; Ferrari N
Int J Cancer; 2009 Jun; 124(12):2989-96. PubMed ID: 19319982
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
10. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Schweizer MT; Carducci MA
Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
[TBL] [Abstract][Full Text] [Related]
11. Development of new drugs in angiogenesis.
Ziche M; Donnini S; Morbidelli L
Curr Drug Targets; 2004 Jul; 5(5):485-93. PubMed ID: 15216914
[TBL] [Abstract][Full Text] [Related]
12. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis of prostate cancer and antiangiogenic therapy.
Uehara H
J Med Invest; 2003 Aug; 50(3-4):146-53. PubMed ID: 13678383
[TBL] [Abstract][Full Text] [Related]
14. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
Ryan CJ; Lin AM; Small EJ
Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and prostate cancer: important laboratory and clinical findings.
Cox MC; Permenter M; Figg WD
Curr Oncol Rep; 2005 May; 7(3):215-9. PubMed ID: 15847713
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis and prostate cancer tumor growth.
Nicholson B; Theodorescu D
J Cell Biochem; 2004 Jan; 91(1):125-50. PubMed ID: 14689586
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
19. [Anti-angiogenic drugs probable complement in cancer therapy].
Christofferson R; Claesson-Welsh L; Muhr C
Lakartidningen; 2002 Oct; 99(42):4138-9, 4142-8. PubMed ID: 12448292
[TBL] [Abstract][Full Text] [Related]
20. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
